@article{article_391066, title={Cisplatin and etoposide in the treatment of elderly patients with advanced non-small cell lung cancer}, journal={Journal of Uludağ University Medical Faculty}, volume={29}, pages={25–28}, year={2003}, author={Kanat, Özkan and Evrensel, Türkkan and Özkan, Atilla and Demıray, Mutlu and Ercan, İlker and Kurt, Ender and Gönüllü, Güzin and Arslan, Murat and Demiray, Hülya and Manavoğlu, Osman}, keywords={Non-small cell lung cancer, Chemotherapy, Elderly patients}, abstract={The aims of the present study were to test activity and tolerability of cisplatin and etoposide in advanced non-small cell lung cancer (NSCLC) patients aged 70 years or higher. Twenty-four patients were enrolled. Cisplatin was given at a dose of 60 mg/m2 on day 1 and etoposide at a dose of 120 mg/m2 on days 1-3. Total 116 courses were administered. Twelve patients (50%) completed all six cycles of treatment. Three patients (12.5%) obtained a partial response, as well as 12 (50%) stable disease and 9 (37.5%) progressive disease. The median survival was 48.5 ± 6.06 weeks, and the 1 year survival rate was 38%. Grade 3-4 neutropenia occurred in 16.6% of patients, grade 4 thrombocytopenia in %4.1, and grade 1-2 neuropathy in 25%. One patient discontinued treatment due to grade 3 nephrotoxicity. In conclusion, cisplatin and etoposide regimen is active and relatively well-tolerated in the treatment of elderly NSCLC patients. New, active and well-tolerated combination regimens could improve present results.}, number={1}, publisher={Bursa Uludağ University}